Democratic Republic of the Congo

Population 2018 84 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>270 (175–385)</td>
<td>321 (208–458)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>31 (9.4–65)</td>
<td>37 (11–77)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>6 (3–10)</td>
<td>7.2 (3.6–12)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>43 (25–65)</td>
<td>51 (30–77)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>10 (3.2–22)</td>
<td>12 (3.8–26)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- % tested with rapid diagnostics at time of diagnosis 7%
- % with known HIV status 60%
- % pulmonary 83%
- % bacteriologically confirmed*** 77%
- % children aged 0-14 years 11%
- % women 39%
- % men 50%

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018 63% (44–97)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 20% (10–33)

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance ***
  - New cases 2%
  - Previously treated cases 66%

Laboratory-confirmed cases*
- MDR/RR-TB: 765, XDR-TB: 22
- MDR/RR-TB: 690, XDR-TB: 15

MDR/RR-TB cases tested for resistance to second-line drugs 328

Treatment success rate and cohort size
- New and relapse cases registered in 2017 90% 149 657
- Previously treated cases, excluding relapse, registered in 2017 70% 1 593
- HIV-positive TB cases registered in 2017 78% 9 688
- MDR/RR-TB cases started on second-line treatment in 2016 86% 634
- XDR-TB cases started on second-line treatment in 2016 39% 18

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment 39%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 24% (22–26)

TB financing, 2019
- National TB budget (US$ millions) 44
  - Funding source: 4% domestic, 55% international, 41% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-02 Data: www.who.int/tb/data